GSK obtains injunction in continuations case
In what must be viewed as a serious reverse for the USPTO, it looks like the pharma company GlaxoSmithKline has obtained an injunction preventing the implementation of the office’s new claims and continuations rules, which were due to come into…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.